Department of Chemistry of Natural and Microbial Products, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Buhouth St., Dokki, P.O. Box 12622, Cairo, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt; Department of Pharmaceutical Chemistry, School of Pharmacy, Newgiza University (NGU), NewGiza, Km 22 Cairo-Alexandria Desert Road, Cairo, Egypt.
Eur J Med Chem. 2022 Jan 15;228:114004. doi: 10.1016/j.ejmech.2021.114004. Epub 2021 Nov 20.
A dual-tail approach was applied to the design of a novel series of 2-thiopyrimidine-benzenesulfonamides as carbonic anhydrase (CA) inhibitors. The design strategy is based on the hybridization between a benzenesulfonamide moiety as Zn binding group and 2,4-disubstituted thiopyridimidine as a tail. Among the synthesized compounds, 14h displayed the highest potency (K = 1.72 nM) and selectivity for CA II over the isoforms CA IX and CA XII with selectivity indexes of 50 and 5.26, respectively. Meanwhile, compounds 14a and 14l displayed a potent inhibitory activity against CA IX (K = 7.4 and 7.0 nM, respectively) compared with the reference drug acetazolamide (AAZ) (K = 25 nM), and compound 14l showed higher potency (K = 4.67 nM) than AAZ (K = 5.7 nM) against the tumor-associated isoform CA XII. Evaluation of the antiproliferative activity in NCI single-dose testing of selected hybrids revealed a pronounced potency of the selective CA II inhibitor 14h against most of the tested NCI cancer cell lines. Moreover, compound 14h demonstrated an IC values ranging from 2.40 to 4.50 μM against MCF-7, T-47D, MDA-MB-231, HCT-116, HT29 and SW-620. These results demonstrate that CA II inhibition can be an alternative therapeutic target for cancer treatment. A cell cycle analysis of MCF-7 and MDA-MB-231 showed that treatment with 14h arrested both cell lines at the G2/M phase with significant accumulation of cells in the pre-G1 phase. Moreover, compound 14h showed a noticeable induction of late apoptosis and necrotic cell death of both cell lines compared with untreated cells as a control. A molecular docking study suggested that the sulfonamide moiety accommodates deeply in the CA active site and interacts with the Zn ion while the dual-tail extension interacts with the surrounding amino acids via several hydrophilic and hydrophobic interactions, which affects the potency and selectivity of the hybrids.
采用双头策略设计了一系列新型 2-嘧啶并-苯磺酰胺类碳酸酐酶(CA)抑制剂。设计策略基于苯磺酰胺部分作为 Zn 结合基团和 2,4-二取代噻嘧啶作为尾巴的杂交。在所合成的化合物中,14h 对 CA II 的活性最高(K=1.72 nM),对同工酶 CA IX 和 CA XII 的选择性分别为 50 和 5.26。同时,化合物 14a 和 14l 对 CA IX 的抑制活性较强(K=7.4 和 7.0 nM),与参考药物乙酰唑胺(AAZ)(K=25 nM)相比,化合物 14l 对肿瘤相关同工酶 CA XII 的活性更高(K=4.67 nM),高于 AAZ(K=5.7 nM)。在 NCI 单剂量测试中对所选杂合体的抗增殖活性评估表明,选择性 CA II 抑制剂 14h 对大多数测试的 NCI 癌细胞系具有显著的活性。此外,化合物 14h 对 MCF-7、T-47D、MDA-MB-231、HCT-116、HT29 和 SW-620 的 IC50 值范围为 2.40 至 4.50 μM。这些结果表明,CA II 抑制可能是癌症治疗的另一种治疗靶点。MCF-7 和 MDA-MB-231 的细胞周期分析表明,用 14h 处理使这两种细胞系都在 G2/M 期停滞,并且在 Pre-G1 期有大量细胞积累。此外,与未处理的细胞作为对照相比,化合物 14h 明显诱导两种细胞系的晚期凋亡和坏死性细胞死亡。分子对接研究表明,磺酰胺部分在 CA 活性部位深容纳,并与 Zn 离子相互作用,而双头延伸通过几个亲水和疏水相互作用与周围的氨基酸相互作用,这影响了杂合体的效力和选择性。